Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 7:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 1,956 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard protocol Clear all
Enrolling by invitation Phase 1Phase 2 Interventional

Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT)

NCT07221565
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Autoimmune Diseases, Chronic Inflammatory Syndromes, Immune Dysregulation
Interventions
Low-Frequency Electromagnetic Resonance Therapy (LF-EMR), Sham Resonance Device (Inactive Control), Low-Dose Naltrexone (LDN)
Device · Drug
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 24, 2026, 7:27 AM EDT
Completed Phase 3 Interventional Results available

Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure

NCT01471028
View directory record Official record
Conditions
Acute Alcoholic Hepatitis
Interventions
ELAD treatment, Standard of care (Control)
Biological · Other
Lead sponsor
Vital Therapies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
35
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 24, 2026, 7:27 AM EDT
Completed Phase 2 Interventional Results available

Abbreviated Protocol for Two-Stage Exchange

NCT04662632
View directory record Official record
Conditions
Prosthetic Joint Infection
Interventions
VT-X7 Treatment System with Tobramycin Sulfate, Standard of Care, Two-stage exchange arthroplasty, VT-X7 Treatment System with Vancomycin Hydrochloride
Combination Product · Drug · Procedure
Lead sponsor
Osteal Therapeutics, Inc.
Industry
Eligibility
22 Years to 84 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
17
States / cities
Phoenix, Arizona • Torrance, California • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 24, 2026, 7:27 AM EDT
Completed Not applicable Interventional

Latino/a Adolescents With Suicidal Behavior

NCT02820636
View directory record Official record
Conditions
Suicide
Interventions
S-CBT, Treatment as Usual
Behavioral
Lead sponsor
Brown University
Other
Eligibility
13 Years to 17 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
East Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Oct 24, 2026, 7:27 AM EDT
Completed Not applicable Interventional

Memory Aid for Informed Consent in Alzheimer's Research

NCT00105612
View directory record Official record
Conditions
Alzheimer's Disease, Aging
Interventions
Memory and Organizational Aid, Standard Informed Consent Process
Device · Behavioral
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
Not listed
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 29, 2009 · Synced Oct 24, 2026, 7:27 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Allergy Testing of Patients Labeled as Penicillin Allergic

NCT02983630
View directory record Official record
Conditions
Drug Hypersensitivity
Interventions
Penicillin allergy testing
Other
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Oct 24, 2026, 7:27 AM EDT
Recruiting Phase 3 Interventional

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

NCT07223814
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Bleximenib, Cytarabine, Daunorubicin or Idarubicin, Placebo
Drug
Lead sponsor
Stichting Hemato-Oncologie voor Volwassenen Nederland
Other
Eligibility
18 Years and older
Enrollment
875 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Orlando, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 24, 2026, 7:27 AM EDT
Active, not recruiting Early Phase 1 Interventional

Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma

NCT06318871
View directory record Official record
Conditions
Renal Carcinoma, Renal Cell Carcinoma, Urothelial Carcinoma, Chromophobe Renal Cell Carcinoma, Translocation Renal Cell Carcinoma
Interventions
Cytokine Induced Memory-like Natural Killer (CIML NK) Cells, Interleukin-2 (IL-2)
Biological · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 24, 2026, 7:27 AM EDT
Completed Phase 4 Interventional Results available

The Kentucky Viral Hepatitis Treatment Study

NCT03949764
View directory record Official record
Conditions
Hepatitis C, Opioid-Related Disorders, Injection Drug Use
Interventions
Sofosbuvir/velpatasvir (Epclusa®)
Drug
Lead sponsor
Jennifer Havens
Other
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Hazard, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 24, 2026, 7:27 AM EDT
Completed Phase 4 Interventional Results available

Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant

NCT04104438
View directory record Official record
Conditions
Asses Immunosuppression Modulation on Renal Recovery Post LT
Interventions
Basiliximab 20 MG
Drug
Lead sponsor
Fady M Kaldas, M.D., F.A.C.S.
Other
Eligibility
18 Years to 78 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 24, 2026, 7:27 AM EDT
Completed Not applicable Interventional

READI (Readiness Evaluation And Discharge Interventions) Study

NCT01873118
View directory record Official record
Conditions
Discharge Transition of Patients Discharged to Home
Interventions
RN-RHDS protocol, RN-RHDS+PT-RHDS protocol, RN-RHDS + PT-RHDS + NIAF
Other
Lead sponsor
Marquette University
Other
Eligibility
18 Years and older
Enrollment
189,796 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 20, 2018 · Synced Oct 24, 2026, 7:27 AM EDT
Completed No phase listed Observational

Impact of Improving Gastrointestinal Symptoms on Autism Symptoms and Oxidative Stress

NCT02442115
View directory record Official record
Conditions
Autistic Disorder, Constipation, Gastrointestinal Diseases
Interventions
Treatment of Functional Constipation by
Other
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
5 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Los Angeles, California • Santa Ana, California
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 24, 2026, 7:27 AM EDT
Completed Not applicable Interventional Results available

A Trauma Informed Adaptation of Mindfulness-Based Relapse Prevention for Women in Substance Use Treatment

NCT03505749
View directory record Official record
Conditions
Substance Use Disorders, Post Traumatic Stress Disorder
Interventions
Trauma Informed Mindfulness-Based Relapse Prevention, Treatment As Usual (TAU)
Behavioral
Lead sponsor
Pacific University
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
5
States / cities
Beaverton, Oregon • Hillsboro, Oregon • Mountaindale, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 24, 2026, 7:27 AM EDT
Active, not recruiting Phase 3 Interventional

RZ358 Treatment for Congenital Hyperinsulinism

NCT06208215
View directory record Official record
Conditions
Congenital Hyperinsulinism
Interventions
RZ358 (5 mg/kg) + SOC (Standard-of-Care) or Placebo + SOC, RZ358 (10 mg/kg) or Placebo + SOC, RZ358 (5-10 mg/kg) + SOC
Drug
Lead sponsor
Rezolute
Other
Eligibility
3 Months to 45 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 24, 2026, 7:27 AM EDT
Completed Phase 1 Interventional

Intravenous Vitamin C in Combination With Standard Chemotherapy for Pancreatic Cancer

NCT00954525
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
Gemcitabine and Erlotinib, Intravenous Vitamin C
Drug · Dietary Supplement
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 24, 2026, 7:27 AM EDT
Recruiting Phase 1 Interventional

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

NCT05733689
View directory record Official record
Conditions
Gastroesophageal Adenocarcinoma
Interventions
FLOT, FOLFOX, FOLFIRI, FOLFIRINOX, PACLITAXEL with or without CARBOPLATIN, DOCETAXEL and IRINOTECAN (alone or combined), NIVOLUMAB (alone or when added to a regimen above), PEMBROLIZUMAB (alone or when added to a regimen above), Durvalumab, Trastuzumab
Combination Product · Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 24, 2026, 7:27 AM EDT
Terminated Phase 2 Interventional Results available

Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment

NCT01521143
View directory record Official record
Conditions
Epithelial Ovarian Cancer
Interventions
Cvac, Placebo
Biological
Lead sponsor
Prima BioMed Ltd
Industry
Eligibility
18 Years and older · Female only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
6
States / cities
Los Angeles, California • Boynton Beach, Florida • Sarasota, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 24, 2026, 7:27 AM EDT
Completed Not applicable Interventional

MRI/MRSI in Risk Assessment of Prostate Cancer Patients

NCT00582543
View directory record Official record
Conditions
Prostate Cancer
Interventions
eMRI/MRSI
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Male only
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 17, 2011 · Synced Oct 24, 2026, 7:27 AM EDT
Recruiting Early Phase 1 Interventional

A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma

NCT06552260
View directory record Official record
Conditions
Glioblastoma, Recurrent Glioblastoma, Brain Tumor
Interventions
Troriluzole
Drug
Lead sponsor
Ugonma Chukwueke
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 24, 2026, 7:27 AM EDT
Completed Phase 1 Interventional Results available

A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies

NCT02327169
View directory record Official record
Conditions
Advanced Nonhematologic Malignancies
Interventions
MLN2480, MLN0128, Alisertib, Paclitaxel, Cetuximab, Irinotecan
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Oct 24, 2026, 7:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Salpingectomy at Cesarean Delivery for Ovarian Cancer Reduction (SCORE)

NCT02374827
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Standard postpartum tubal ligation, Complete Salpingectomy
Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
25 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Oct 24, 2026, 7:27 AM EDT
Completed Phase 4 Interventional Results available

Comparing the Effectiveness of New Versus Older Treatments for Attention Deficit Hyperactivity Disorder (The NOTA Study)

NCT00889915
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate transdermal system, Lisdexamfetamine dimesylate, Osmotic-release oral system methylphenidate (OROS MPH), Mixed amphetamine salts extended release
Drug
Lead sponsor
Duke University
Other
Eligibility
6 Years to 17 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Oct 24, 2026, 7:27 AM EDT
Completed Not applicable Interventional Results available

Developing an Imaging-Based Tool to Identify Areas for Prostate Cancer Biopsy

NCT03585660
View directory record Official record
Conditions
Prostate Cancer
Interventions
Diagnostic MRI, Diagnostic Prostate Biopsy, Risk Map DSS tool
Procedure · Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 24, 2026, 7:27 AM EDT
Active, not recruiting Not applicable Interventional

A Positive Psychology Based Intervention (PATH-C) for Caregivers of HSCT Survivors

NCT06153797
View directory record Official record
Conditions
Hematologic Malignancy, Caregiver
Interventions
PATH-C
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 24, 2026, 7:27 AM EDT